Best Life Sciences Platforms and Tools Companies in Utah, United States

Developer of epigenetic diagnostics and therapeutics for complex diseases. It focuses on identifying dysregulation across multiple genes and related pathways. It aims to transform the diagnosis and treatment of complex diseases like infertility through its epigenetic platform. The company's initial product, SpermQT, seeks to improve fertility testing and provide personalized treatment plans.

Funding rounds

• Apr 2025Grant (prize money)$1.9M
• Feb 2025Grant (prize money)$1.9M
• Jan 2025Grant (prize money)$1.9M
• Feb 2024Grant (prize money)$1M

Founders & team

Kristin BrogaardCo-Founder & CSOAndy OlsonCo-Founder & CEOKristin BrogaardCo-Founder & COO

Investors

NIH, Propel Bio Partners, Portfolia, Alliance of Angels, Kickstart Seed Fund, Park City Angels

Carterra develops SPR based platforms to study enzyme kinetics. The company provides users with instruments and services that enable multiplexing on planar array surfaces. It has developed mAb characterization technology called LSA which is used to study epitope binding/mapping, kinetics, and quantitation. It also offers Continuous Flow Microspotter (CFM), which includes an array printing instrument and a microfluidic print head. Its products include spot CFM printhead, which uses a network of microchannels to deposit samples at one time in a block; and CFM instrument, which uses built-in sensors and pumps to control the flow within the CFM print head.

Funding rounds

• Dec 2023Series G$5M
• Dec 2020Series G$8.1M
• Dec 2019Series F$6M
• Aug 2018Series E$4.5M

Founders & team

Christian GiddensDirector Of Sales

Investors

Ballast Point Ventures, Telegraph Hill Partners, Frazier VC, PerkinElmer, NIH SBIR/STTR, HHS

Tech stack

Cart FunctionalityCloudflareCloudflare Bot ManagementCookiebotCore-JsCrazy Egg

Lipid and cell signaling solutions for diagnostics and drug treatments. They develop research reagents and assays focused on lipid and cell signaling to advance diagnostics and drug treatments for debilitating diseases. They offer a comprehensive range of products including lipids, bioassays & kits, antibodies & proteins, peptides, and biochemical reagents. Services include assay services, LNP services, custom synthesis, and nanobody production. Their mission is to empower scientific discovery by providing high-quality solutions in lipid synthesis, formulation, and analysis. They collaborate with scientists, providing expert insight and dedicated support to accelerate breakthroughs. They are committed to social responsibility, fostering a sustainable future, supporting diversity & inclusion, environmental stewardship, and ethical business practices. They offer technical support, FAQs, and resources to assist researchers in their work.

Funding rounds

• Sep 2024Grant (prize money)$399.3K
• Jan 2019Grant (prize money)$300K
• Aug 2014Grant (prize money)$224.3K
• Nov 2011Grant (prize money)$625.2K

Founders & team

Jeremy AmbersonPresident and CEO

Investors

NIH, HHS, National Science Foundation

Tech stack

AlgoliaAosCloudflareCloudflare Bot ManagementCore-JsGoogle Analytics

Developer of reagents that specifically bind denatured collagen. It offers Collagen Hybridizing Peptides molecules designed to bind with unfolded or damaged collagen allowing sensitive detection in research and diagnostic applications. The applications include histopathology, tissue damage detection, cancer cell invasion assays, mechanical injury mapping in tissues, and in vivo Imaging.

Funding rounds

• Oct 2023Series A$3.7M
• Mar 2022Seed—
• Apr 2016Grant (prize money)$1.6M

Founders & team

Yang LiFounder & CEOMike KirknessCEO

Investors

BASF, HHS, Altitudelab, Utah Innovation Fund

Tech stack

WordpressJavaMysqlPhpUnixOpenssl

Biological agent identification products and services for biodefense and first responders. The company delivers fully integrated biological agent identification products, including systems and test kits, to the biodefense and first responder community. They speed up medical results, help people stay healthy, and make communities more secure. The company focuses on molecular diagnostics and biosurveillance industries, offering rapid PCR detection technologies. Their products include systems and panels that test for viruses, bacteria, and protozoa, using automated capabilities like sample preparation, reverse transcription for RNA viruses, and multiplex PCR. They provide solutions for identifying biological threat agents and ensuring water systems are safe. The company aims to make the world a healthier and safer place through product innovation.

Funding rounds

• Aug 2014Grant (prize money)$168K
• Jul 2013Grant (prize money)$3.6M
• Jan 2013Grant (prize money)$452.6K
• Jul 2012Grant (prize money)$262.1K

Founders & team

Randy RasmussenCo-Founder & CEO

Investors

HHS

Tech stack

Apple Icloud MailBigcommerceCloudflareCloudflare Bot ManagementCore-JsDocusign

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.

Founders & team

Dwight EganCo-Founder & CEOBrent SatterfieldCo-Founder & CSO

Investors

NIH, SALSS

Tech stack

WordpressMysqlPhpHello ElementorVimeoWoocommerce

BioMicro Systems serves the life sciences community by developing and marketing biological research products based on its proprietary microfluidic and microarray technologies. Its products include MAUI hybridization systems, disposable MAUI Mixer microarray hybridization chambers combined with microarray hybridization instrument. It also offers Kits for FISH, arrayCGH, microRNA microarrays, gene expression microarrays, and protein arrays. BioMicro Systems was closed as of Sep 2010.

Animal and plant cell culture media and reagents manufacturer, a manufacturer and supplier of products for animal cell culture and plant research. They offer cell culture media, fetal bovine serum, buffer solutions, antimicrobials, and other reagents. For plant research and micropropagation, they provide tissue culture media, plant growth regulators, agars, and biochemicals. They focus on understanding customer processes and workflows to meet budgets and timelines. They develop open relationships with customers, inviting feedback and searching for ways to innovate and improve existing systems. They provide high-quality products and custom formulations for bench-top or production sales. They offer a range of products, including animal cell culture supplies, plant biology reagents, and orchid media. They also provide vessels, instruments, and supplies for cell and tissue culture applications.

Thera target engages in developing polymer drug carrier systems through conjugations. This technology involves water soluble degradable polymer drug carrier that will deliver a variety of bound anti-cancer drugs directly to solid cancer tumors. The polymer conjugates to the drug or effective delivery. Additionally, the company also develops gel-forming silk-elastin like protein polymer (SELP) for localized delivery of the chemotherapeutic agent.

Provider of a portable device for nucleic acid testing. Their platform, Xtreme Chain Reaction (XCR) consists of proprietary assay design and amplification methodologies. XCR utilizes a patented combination of target design and template selection to deliver amplification and detection. Their flagship product is Portable Nucleic Acid Testing System (pNATS) which is a proprietary testing system designed to be utilized in a laboratory setting or transported to a near-patient environment in which compromised or hard-to-reach patients can be tested.

Provider of transgenic tools for drug discovery and other life science research. The company uses CRISPR to create custom genetically engineered model organisms for early drug discovery. It also provides contract research services based on its platform. The company uses software solutions such as Benchling to enable easy data sharing and transfer, Currently, transgenic services are available for C. elegans and zebrafish.

Developer of PCR-based products for molecular biology. The company has developed sample transfer and aliquoting technology (AlluviaSystem) which enables two-step PCR. It is applicable in DNA methylation analysis and pathogen detection. Their consumables include Plate Loading Manifolds and Gel Loading Manifolds.

Funding rounds

• Jan 2018Seed$1.5M

Founders & team

Rob ParryCEO